<DOC>
	<DOCNO>NCT02980029</DOCNO>
	<brief_summary>The purpose study determine study drug , TVB-2640 , able affect level certain enzyme subject 's blood cause change tumor . This study people require surgery colon cancer .</brief_summary>
	<brief_title>Pharmacodynamic Effects Fatty Acid Synthase ( FASN ) Inhibition With TVB-2640 Resectable Colon Cancer</brief_title>
	<detailed_description>The Purpose study evaluate pharmacodynamic effect metabolic endpoint ( malonyl carnitine tripalmitin level ) follow short-term treatment TVB-2640 patient resectable colon cancer.48 evaluable patient enrol study . The accrual rate estimate 4 per month .</detailed_description>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm , resectable colon cancer without distant metastasis , candidate surgical resection tumor . Willing able provide write informed consent prior initiation study procedure . Male female ≥ 18 year age day sign informed consent Eastern Cooperative Oncology Group ( ECOG ) performance status 0 ( fully active , able carry predisease activity without restriction ) 1 ( unable perform physically strenuous activity ambulatory able carry work light sedentary nature ) . Adequate bone marrow function evidence : 1 . Hemoglobin ≥ 9 g/dL 2 . ANC count ≥ 1.5 X 109/L 3 . Platelets ≥ 100 X 109/L No significant ischemic heart disease myocardial infarction ( MI ) within 6 month first dose study drug currently adequate cardiac function , evidence left ventricular ejection fraction ( LVEF ) ≥ 50 % assess multigated acquisition ( MUGA ) ultrasound/echocardiography ( ECHO ) ; correct QT interval ( QTc ) &lt; 470 msec Female subject childbearing potential negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . Female patient childbearing potential willing use 2 method birth control , surgically sterile , abstain heterosexual activity course study 90 day last dose study medication . Subjects childbearing potential surgically sterilize free menses &gt; 1 year . Male patient agree use adequate method contraception start first dose study therapy 90 day last dose study therapy , document surgically sterile Willing participate study comply study requirement . Inability swallow oral medication impairment GI function GI disease may significantly alter drug absorption ( include , limited active inflammatory bowel disease , malabsorption syndrome ) . Concomitant therapy antacid antiemetic permissible History risk factor torsades de pointes ( e.g. , heart failure , hypokalemia , family history long QT syndrome ) . Concomitant use medication low risk QT/QTc prolongation ( include , limited diphenhydramine , famotidine , ondansetron ) permissible . Known psychiatric substance abuse disorder would interfere cooperation requirement trial . Having receive cancerdirected therapy ( chemotherapy , radiotherapy , hormonal therapy , biologic immunotherapy , etc ) investigational drug within 4 week ( 6 week mitomycin C nitrosoureas ) 5 halflives agent ( whichever short ) first dose study drug . Pregnant , breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 90 day last dose trial treatment Inoperable basis coexistent medical problem History clinically significant dry eye ( xerophthalmia ) corneal abnormality , contact lens wearer , agree abstain contact lens use Day 1 last dose study drug . Other concurrent disease ( cardiovascular , renal , hepatic , etc . ) laboratory abnormality , investigator 's opinion would increase risk participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>